Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ContraFect gains lysin from Rockefeller University; deal expanded

Executive Summary

Rockefeller University has licensed ContraFect Corp. (develops protein and antibody therapeutics for infectious diseases) a potent lysin, named CF301 by the company, aimed at staphylococcus infections including methicillin-resistant and vancomycin-resistant strains.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies